SCHEMBL3102687

SCHEMBL3102687

CC(Oc1cc2sc(-c3ccc(OC(N)=O)cc3)nc2cc1F)c1c(Cl)cccc1Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
KDM4E B2RXH2 2/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
KMT2A Q03164 2/20 0.40
MET P08581 6/20 0.39
KDR P35968 5/20 0.39
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
POLB P06746 1/20 0.39
GAA P10253 1/20 0.39
PKM P14618 1/20 0.39
HPGD P15428 1/20 0.39
HTT P42858 1/20 0.39
ATM Q13315 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
ILK Q13418 3/20 0.39
TP53 P04637 2/20 0.38
APP P05067 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3104495 0.92 MET (0.44) MAPTSMN1; SMN2KDM4ENPC1RAB9A
SCHEMBL3111317 0.91 MET (0.49) METKDRFGFR2AXLFLT3
SCHEMBL3102401 0.90 MET (0.42) MAPTSMN1; SMN2KDM4ENPC1RAB9A
SCHEMBL3099137 0.87 APP (0.45) MAPTSMN1; SMN2KDM4ENPC1RAB9A
SCHEMBL3106479 0.86 MET (0.49) MAPTSMN1; SMN2KDM4ENPC1RAB9A
SCHEMBL3102677 0.86 DYRK1A (0.40) MAPTSMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL3110482 0.84 MET (0.48) METKDRFGFR2AXLFLT3
SCHEMBL3109618 0.82 FFAR1 (0.40) MAPTSMN1; SMN2KDM4ENPC1RAB9A
SCHEMBL3104758 0.81 APP (0.47) MAPTKDM4ENPC1RAB9AALDH1A1
SCHEMBL3108713 0.81 MET (0.56) METKDRAPPFGFR2AXL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188078-B2 6-aryl/heteroalkyloxy benzothiazole and benzimidazole derivatives, method for preparing same, application thereof as drugs, pharmaceutical compositions and novel use in particular as C-MET inhibitors SANOFI-AVENTIS (FR) 2012-05-29 US disclosed
US-20100273793-A1 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS c-MET INHIBITORS SANOFI-AVENTIS (FR) 2010-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273793-A1 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS c-MET INHIBITORS MET, ALK, JAK2 MAPT 2894/4885SMN1; SMN2 4485/4885KDM4E 995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.